Home / Publications / Pain Research Forum / Papers of the Week / Reductions in Acute Medication Use and Healthcare Resource Utilization in Patients with Chronic Migraine: A Secondary Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab with Open-Label Extension (REGAIN).
Reductions in Acute Medication Use and Healthcare Resource Utilization in Patients with Chronic Migraine: A Secondary Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab with Open-Label Extension (REGAIN).
To analyze secondary objectives of the REGAIN study related to acute headache medication use and healthcare resource utilization (HCRU) in patients with chronic migraine treated with galcanezumab, a monoclonal antibody to calcitonin gene-related peptide.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
